Trevi Therapeutics (TRVI) EBITDA (2018 - 2026)

Trevi Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$13.0 million for Q1 2026.

• On a quarterly basis, EBITDA fell 27.61% year-over-year to -$13.0 million in Q1 2026; TTM through Mar 2026 was -$50.9 million, a 2.11% decrease from a year earlier, with the FY2025 full-year figure at -$49.3 million, up 4.26% from the prior year.
• EBITDA retreated to -$13.0 million in Q1 2026 per TRVI's latest filing, from -$10.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$6.7 million in Q4 2022 and bottomed at -$14.1 million in Q3 2024.
• The 5-year median for EBITDA is -$10.2 million (2025), against an average of -$10.4 million.
• Across the five-year window, EBITDA rose 19.53% in 2022 and plunged 58.54% in 2024, its largest moves.
• Year by year, EBITDA stood at -$6.7 million in 2022, then tumbled by 34.19% to -$8.9 million in 2023, then tumbled by 37.05% to -$12.2 million in 2024, then gained by 16.52% to -$10.2 million in 2025, then retreated by 27.22% to -$13.0 million in 2026.
• Per Business Quant, the three latest TRVI EBITDA figures stand at -$13.0 million (Q1 2026), -$10.2 million (Q4 2025), and -$13.9 million (Q3 2025).